Increased warfarin consumption and residual fibrin turnover in thrombotic patients with primary antiphospholipid syndrome

Thrombosis Research

Volumn 127, Issue 6, 2011, Pages 595-599

  Ames, Paul R J ^a   Margaglione, Maurizio ^b   Ciampa, Antonio ^c   Colaizzo, Donatella ^d   Ferrara, Felicetto ^e   Iannaccone, Luigi ^e   Vincenzobrancaccio, ^e  

^a AIREDALE GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF FOGGIA   (Italy)

^c S G MOSCATI HOSPITAL   (Italy)

^d CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^e CARDARELLI HOSPITAL   (Italy)

Author keywords

primary antiphospholipid syndrome; warfarin consumption

Indexed keywords

CARDIOLIPIN ANTIBODY; CYTOCHROME P450 2C9; D DIMER; DECARBOXYPROTHROMBIN; FIBRIN; MENADIONE EPOXIDE; VITAMIN K GROUP; WARFARIN;

ADULT; AGE; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG DOSE COMPARISON; DRUG USE; EPOXIDATION; FEMALE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEX DIFFERENCE; THROMBOPHILIA; THROMBOSIS;

ADMINISTRATION, ORAL; ADULT; ANTIBODIES, ANTIPHOSPHOLIPID; ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; ARYL HYDROCARBON HYDROXYLASES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FIBRIN; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; POLYMORPHISM, SINGLE NUCLEOTIDE; THROMBOSIS; WARFARIN;

EID: 79957611909     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2011.01.014     Document Type: Article

References (28)

1. Cervera R, Khamashta MA, Shoenfeld Y, et al. Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicenter prospective study of 1, 000 patients. Ann Rheum Dis 2009;68:1428-32.
2. Ruiz-Irastorza G, Hunt BJ, Khamashta MA. A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies. Arthritis Rheum 2007;57:1487-95. (Pubitemid 350308848)
3. Ames PRJ, Ciampa A, Margaglione M, Iannaccone L, Scenna G, Brancaccio V. Bleeding and re-thrombosis in primary antiphospholipid syndrome on oral anticoagulation. A 8-year longitudinal comparison with mitral valve replacement and inherited thrombophilia. Thromb Haemost 2005;93:694-9.
4. Urbanus RT, de Laat HB, de Groot PG, Derksen RHWM. Prolonged Bleeding Time and Lupus Anticoagulant. A Second Paradox in the Antiphospholipid Syndrome. Arthrits Rheum 2004;50:3605-9.
5. Schwartz S, Siegel R, Getsy J, Callegari P. Fibromyalgia and resistance to warfarin therapy in a patient with systemic lupus erythematosis and antiphospholipid syndrome. J Clin Rheumatol 1996;2:279-82. (Pubitemid 26398669)
6. Hulse ML. Warfarin resistance: diagnosis and therapeutic alternatives. Pharmacotherapy 1996;16:1009-17. (Pubitemid 26403640)
7. D'Andrea G, D'Ambrosio R, Margaglione M. Oral anticoagulants: Pharmacogenetics Relationship between genetic and non-genetic factors. Blood Rev 2008;22: 127-40.
8. Finazzi G, Marchioli R, Brancaccio V, et al. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost 2005;3:848-53. (Pubitemid 41632808)
9. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295-306.
10. Wilson WA, Gharavi AE, Koike T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999;42:1309-11. (Pubitemid 30265586)
11. Palareti G, Cosmi B, Legnani C, et al. PROLONG Investigators. D-dimer testing to determine the duration of anticoagulation therap. N Engl J Med 2006;26(355): 1780-9. (Pubitemid 44631361)
12. Greaves M, Cohen H, Machin SJ, Mackie IJ. Guidelines on the investigation and management of the antiphospholipid syndrome. Br J Haematol 2000;109:704-15. (Pubitemid 30609746)
13. Brancaccio V, Ames PRJ, Glynn J, Iannaccone L, Mackie IJ. A rapid screen for lupus anticoagulant (LA) by comparing a sensitive and insensitive aPTT reagent provides also good discrimination from oral anticoagulants, congenital factor deficiency and heparin. Blood Coagul Fibrinolysis 1997;8:155-60. (Pubitemid 27241507)
14. D'Andrea G, D'Ambrosio RL, Di Perna P, et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 2005;105:645-9. (Pubitemid 40070748)
15. Margaglione M, D'Andrea G, Giuliani N, et al. Inherited prothrombotic conditions and premature ischemic stroke: sex difference in the association with factor V Leiden. Arterioscler Thromb Vasc Biol 1999;19:1751-6. (Pubitemid 29323835)
16. Margaglione M, Brancaccio V, Giuliani N, et al. Increased Risk for Venous Thrombosis in Carriers of the Prothrombin GNA 20210 Gene Variant. Ann Intern Med 1988;129:89-93.
17. Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999;353:717-9. (Pubitemid 29103806)
18. Furie B, Bouchard BA, Furie BC. Vitamin K-Dependent Biosynthesis of γ-Carboxyglutamic Acid. Blood 1999;93:1798-808. (Pubitemid 29128479)
19. Iuliano L, Praticò D, Ferro D, et al. Enhanced Lipid Peroxidation in Patients Positive for Antiphospholipid Antibodies. Blood 1997;90:3931-5. (Pubitemid 27484045)
20. Ames PRJ, Nourooz-Zadeh J, Tommasino C, Alves J, Brancaccio V, Anggard EE. Oxidative stress in primary antiphospholipid syndrome. Thromb Haemost 1998;79:447-9.
21. Wajih N, Hutson SM, Wallin R. Disulfide-dependent Protein Folding Is Linked to operation of the Vitamin K Cycle in the Endoplasmic Reticulum. A protein disulfide isomerase-VKORC1 redox enzyme complex appears to be responsible for vitamin K1 2,3-epoxide reduction. J Biol Chem 2007;282:2626-35. (Pubitemid 47076752)
22. Booth SL, Golly I, Sacheck JM, et al. Effect of vitamin E supplementation on vitamin K status in adults with normal coagulation status. Am J Clin Nutr 2004;80:143-8. (Pubitemid 41115568)
23. Roberts II LJ, Oates JA, Linton MF, et al. The relationship between dose of vitamin E and suppression of oxidative stress in humans. Free Radic Biol Med 2007;43: 1388-93. (Pubitemid 47532362)
24. Praticò D, Ferro D, Iuliano L, et al. Ongoing Prothrombotic State in Patients With Antiphospholipid Antibodies: A Role for Increased Lipid Peroxidation. Blood 1999;93:3401-7. (Pubitemid 29220907)
25. Ames PR, Tommasino C, D'Andrea G, Iannaccone L, Brancaccio V, Margaglione M. Thrombophilic genotypes in subjects with idiopathic antiphospholipid antibodies: prevalence and significance. Thromb Haemost 1998;79:46-9. (Pubitemid 28037055)
26. Cappucci G, Margaglione M, Ames PRJ. Comparative prevalence of antiphospholipid antibodies and thrombophilic genotypes in consecutive patients with venous thrombosis. Blood Coagul Fibrinolysis 2001;12:659-65. (Pubitemid 33139685)
27. Ames PRJ, Scenna G, Antinolfi I, Gaeta G, Margaglione M, Margarita A. Atherosclerosis in thrombotic primary antiphospholipid syndrome. J Thromb Haemost 2009;7:537-42.
28. Allman-Farinelli MA, Dawson B. Diet and aging: bearing on thrombosis and hemostasis. Semin Thromb Hemost 2005;31:111-7 (Pubitemid 40262145)